AbbVie

Pharmaceuticals, Biotechnology and Life Sciences

Targets set1.5°C

SBTI ID

40009630

Informations générales

Localisation

United States of America

Northern America

Secteur d'activité

Pharmaceuticals, Biotechnology and Life Sciences

Type d'organisation

Corporate

Dernière mise à jour

27/04/2023

Objectifs à court terme (Near-Term)
Engagement de réduction des émissions à horizon 2030

Statut

Targets set

Classification

1.5°C

Année cible

2030

Progression vers l'objectif73%
2015 (année de référence)2030
Description complète des objectifs

AbbVie commits to reduce absolute scope 1 and 2 GHG emissions 42.0% by 2030 from a 2021 base year*. AbbVie also commits to increase active sourcing of renewable electricity from 29.5% in 2021 to 100.0% by 2030. AbbVie further commits that 79.1% of its suppliers by emissions covering purchased goods and services, capital goods, and upstream transportation and distribution, will have science-based targets by 2027. * The target boundary includes land-related emissions and removals from bioenergy feedstocks.

Business Ambition 1.5°C

Statut

BA1.5 member

Date d'engagement

17/06/2021

Classification détaillée

The targets covering greenhouse gas emissions from company operations (scopes 1 and 2) are consistent with reductions required to keep warming to 1.5°C

Identifiants

ISIN

US00287Y1091

LEI

5493006BTKYVSIO64269

Source : Science Based Targets initiative | Données publiques